louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04957654: Vestibular Socket Therapy in Immediate Implants With Grafting Materials
Official title: A Comparative Study Evaluating Vestibular Socket Therapy in Immediate Implants Using Different Grafting Materials
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Tooth Extraction
Dental Implant
Extarction Socket
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2021-07-12
Enrollment: 24
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The current research aims at evaluating the outcomes of the vestibular socket therapy in immediate implants using collagen plug, demineralized freeze-dried bone allograft, and deproteinized bovine bone minerals at both radiographic and clinical levels


Eligibility criteria: Inclusion Criteria:

* Patients will be included if they have one or more hopeless teeth without signs of acute infection in the maxillary anterior region.
* Remaining roots or non-restorable teeth with sufficient bone apically and palatably to allow proper implant positioning with sufficient primary stability.
* Optimal compliance as evidenced by no missed treatment appointments and a positive attitude towards oral hygiene.
* Medically free

Exclusion Criteria:

* Medically compromised patients and systemic conditions precluding implant and periodontal surgery.
* Smokers, diabetics, pregnant or lactating women.
* History of chemotherapy, radiotherapy in head and/or neck region.
* Bisphosphonate therapy

Primary outcomes:
measure: changes in facial plate thickness
timeFrame: at baseline, 6 and 12 months
measure: changes in facial plate height
timeFrame: at baseline, 6 and 12 months
Secondary outcomes:
measure: changes in peri-implant mucosal level
timeFrame: at baseline, 3rd and 6th months
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Faculty of Dentistry, Tanta University
Study officials:
References:
Clinical trial NCT04701554: EFFECT OF A 16-SESSION QIGONG PROGRAM ON PHYSICAL AND MENTAL HEALTH IN PATIENTS WITH LYMPHOMA: A RANDOMIZED CONTROLLED TRIAL
Official title: EFFECT OF A 16-SESSION QIGONG PROGRAM ON PHYSICAL AND MENTAL HEALTH IN PATIENTS WITH LYMPHOMA: A RANDOMIZED CONTROLLED TRIAL
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lymphoma
Lead sponsor: Universidad de Granada
Sponsor class: OTHER
First posted: 2021-01-08
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A ramdomized controlled trial.
Primary purpose: TREATMENT

Brief summary: The aim of the present study was to investigate in lymphoma patients the effects of a 16-session qigong programme (2 times a week) on physical and psychological parameters.

Detailed description: A randomized controlled trial was conducted (control group = 19; intervention = 20). Initially 50 patients enrolled in this study but only 39 finalized the program. 52% male and 48% female with a mean (SD) age of 44.49 (10.60) years. People who have had previous experiencie in mind body practices were excluded. All the patientes received information about the study and informed consent was obtained from all participants. This study was approved by the CEI-GR (C-9) ethics committee and followed the principies of the Declaration of Helsinki.

Eligibility criteria: Inclusion Criteria:

* 18 years and older; lymphoma histology graded I to IIIA.

Exclusion Criteria:

* Treatment that modifies the vegetative nervous system activity; people that have previous experience in mind body practices.

Primary outcomes:
measure: Change from Baseline in Anxiety and Depression on the Hospital Anxiety and Depression Scale (HADS) after 2 months.
timeFrame: Baseline and after 2 months.
measure: Change from Baseline in Happiness on the Lima happiness questionnaire after 2 months.
timeFrame: Baseline and after 2 months.
measure: Change from Baseline in Trial Making Test after 2 months.
timeFrame: Baseline and after 2 months.
measure: Change from Baseline in Heart rate variability after 2 months.
timeFrame: Baseline and after 2 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Granada
country: Spain
facility: Lourdes Díaz Rodríguez
Study officials:
References:
Clinical trial NCT02929654: Assessment of Blood Glucose Monitoring Devices With New Insight Features
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Lead sponsor: LifeScan
Sponsor class: INDUSTRY
First posted: 2016-10-11
Enrollment: 267
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: OTHER

Brief summary: To investigate whether novel insight features in new BGMs can improve glycemic control.


Eligibility criteria: Inclusion Criteria Summary:

* Diagnosed with T1DM or T2DM for ≥ 3 month prior to screening
* Currently performing SMBG at home for diabetes management decisions
* Willingness to notify the study staff if they become pregnant during the study
* Willing to sign an informed consent

Exclusion Criteria Summary:

* Is unlikely to be compliant with the diabetes regimen in the opinion of study staff
* Currently pregnant or planning pregnancy within duration of study or breast feeding; subjects who become pregnant during the study will be withdrawn
* Conflict of Interest

Primary outcomes:
measure: A1c change from baseline after 12 weeks
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United Kingdom
facility: Diabetes Centre, Heartlands Hospital
city: Edinburgh
country: United Kingdom
facility: NHS Lothian
city: Inverness
country: United Kingdom
facility: Highland Diabetes Institute
Study officials:
affiliation: LifeScan Scotland
name: Mike Grady
role: STUDY_DIRECTOR
References:
citation: Grady M, Katz LB, Levy BL. Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients With Diabetes in Comparison to Blood Glucose Meters Without Color (ACCENTS Study). J Diabetes Sci Technol. 2018 Nov;12(6):1211-1219. doi: 10.1177/1932296818775755. Epub 2018 May 31.
Clinical trial NCT03482154: Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Official title: Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stem Cell Transplant Complications
Hyperglycemia
Hypoglycemia
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2018-03-29
Enrollment: 344
Sex: ALL
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who received hematopoietic stem cell transplants with the Bone Marrow Transplant Program at Children's Hospital Colorado from January 1, 2007 to July 31, 2016.

Brief summary: This is a retrospective chart review of patients who underwent a hematopoietic stem cell transplant (HSCT) between 1994 and 2016 to evaluate incidence of malglycemia and the relationship to specific outcomes.

Detailed description: This is a retrospective chart review of patients who underwent a hematopoietic stem cell transplant between 2007 and 2016 to evaluate incidence and risk factors of malglycemia. The review will also aim to characterize relationships between specific outcomes and malglycemia in pediatric HSCT patients.

Eligibility criteria: Inclusion Criteria:

* Age 0 to 30 years old at time of transplant
* Bone Marrow Transplant (BMT) recipient at Children's Hospital Colorado (CHCO) between 1/1/2007 and 7/31/2016

Exclusion Criteria:

* Preexisting diabetes mellitus or known hyperglycemia
* Inadequate blood glucose data for analysis

Primary outcomes:
measure: Number of patients experiencing malglycemia in primary admission for pediatric HSCT patients
timeFrame: Transplant Day -14 to +100
measure: Number of patients with versus without malglycemia who experience infection
timeFrame: Transplant Day 0 to +100
Secondary outcomes:
measure: Determine whether specific exposures are associated with increased occurrence of malglycemia
timeFrame: Transplant Day -14 to +100
measure: Survival rate of patients with versus without malglycemia
timeFrame: Transplant Day 0 through date of relapse or death
measure: Occurrence of graft-versus-host disease (GVHD) in patients with versus without malglycemia
timeFrame: Transplant Day 0 through date of relapse or death
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Children's Hospital Colorado
state: Colorado
Study officials:
affiliation: Children's Hospital Colorado
name: Jenna Sopfe, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sopfe J, Pyle L, Keating AK, Campbell K, Liu AK, Wadwa RP, Verneris MR, Giller RH, Forlenza GP. Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients. Blood Adv. 2019 Feb 12;3(3):350-359. doi: 10.1182/bloodadvances.2018021014.
Clinical trial NCT03322254: How Respiratory Pathogens Panel Results Affect Patients' Plan of Care
Official title: Medical Provider Assessment On Healthcare Decisions Post-Testing of Respiratory Pathogens (RP Panel) Along With Risk Reducing, and Preventative Strategies
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Respiratory Disease
Lead sponsor: Data Collection Analysis Business Management
Sponsor class: OTHER
Collaborators: name: PAS Research Services
First posted: 2017-10-26
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Current standard operating procedures for providers

Brief summary: Reviewing providers' current standard operating procedure on Respiratory Pathogen testing

Detailed description: The general design of this study is collecting data and reviewing Principal Investigators' Standard Operating Procedures on Respiratory Pathogen testing and changes made to their specific SOP.

Eligibility criteria: Inclusion Criteria:

* Must be a Medical Practitioner

  * Medical Doctor (MD)
  * Doctor of Osteopathic (DO)
  * Physician Assistant (PA)
  * Advanced Practice Registered Nurse (APRN)
  * Nurse Practioner (NP)
* Must have a current standard operating procedure that includes obtaining/reviewing medical history.

Exclusion Criteria:

* Government-funded insurance data cannot be included in the study.

Primary outcomes:
measure: Provider Structures and Processes
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Land O' Lakes
country: United States
facility: DCABM
state: Florida
Study officials:
References:
Clinical trial NCT02150954: Foley Bulb With Low Dose Pitocin Versus Foley Bulb With a Standard Incremental Infusion Protocol for the Induction of Labor
Official title: A Randomized Comparison of Foley Bulb With Low Dose Pitocin Versus Foley Bulb With a Standard Incremental Infusion Protocol for the Induction of Labor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Induction of Labor
Keywords: induction of labor
pitocin
foley bulb
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2014-05-30
Enrollment: 121
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to compare induction of labor using a foley catheter bulb with a low dose of oxytocin versus a foley catheter bulb with an increasing dose of oxytocin. A foley catheter bulb with or without oxytocin is a common method of labor induction in patients whose cervix is not significantly dilated or thinned out (effaced). Oxytocin (pitocin) is a medicine used to increase the number and strength of the womb's contractions.


Eligibility criteria: Inclusion Criteria:

1. Patients with a singleton pregnancy
2. Term pregnancy (\> 37 weeks gestation)
3. Age ≥ 18 years
4. Bishop score \< 5
5. Contractions \< 6/hr
6. Reassuring fetal heart tracing

Exclusion Criteria:

1. Rupture of membranes
2. Antepartum bleeding
3. Fetal death
4. Placenta previa or low lying placenta
5. Active genital herpes infection
6. Previous use of an induction or preinduction agent during the current pregnancy
7. EFW \>4500 grams
8. Non reassuring fetal testing
9. Inability to pass foley through cervix
10. Prior cesarean section

Primary outcomes:
measure: Time to the Second Stage of Labor
timeFrame: foley bulb placement until second stage of labor (during admission for delivery, up to approximately 4 days)
measure: Time to Delivery
timeFrame: foley bulb placement until delivery (during admission for delivery, up to approximately 4 days)
Secondary outcomes:
measure: Rate of Cesarean Delivery
timeFrame: during admission for delivery, up to approximately 4 days
measure: Time to Active Labor
timeFrame: during admission for delivery, up to approximately 4 days
measure: Time to Foley Expulsion or Removal
timeFrame: foley bulb placement until removal, up to 10 hours
measure: Incidence of Uterine Hyperstimulation
timeFrame: during admission for delivery, up to approximately 4 days
measure: Neonatal Outcome: Birthweight
timeFrame: at time of birth (0 to 1 hour)
measure: Neonatal Outcome: Placental Abruption
timeFrame: during admission for delivery, up to approximately 4 days
measure: Neonatal Outcome: Late Fetal Heart Rate Decelerations
timeFrame: during admission for delivery, up to approximately 4 days
Other outcomes:
Locations:
Study officials:
affiliation: Duke University
name: Chad Grotegut, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Duke University
name: Brennan Fitzpatrick, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04604054: The Effect of Granulocyte Colony Stimulating Factor Versus Human Chorionic Gonadotropin in Females With a History of RIF
Official title: Comparative Study Between Granulocyte Colony Stimulating Factor and Human Chorionic Gonadotropin in Patients With History of Recurrent Implantation Failure in Intra Cytoplasmic Sperm Injection (at Ovum Pick up Day)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Fertility Disorders
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2020-10-27
Enrollment: 100
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: One hundred patients who suffered from recurrent implantation failure in intracytoplasmic sperm injection (ICSI) were allocated in the study. On ovum pick-up day, 50 of them were intrauterine injected with granulocyte colony-stimulating factor (G-CSF) and the other 50 were injected with intrauterine Human Chorionic Gonadotropins (HCG). The clinical pregnancy rate was evaluated as a primary outcome and ultrasound imaging of the gestational sac was evaluated as a secondary outcome

Detailed description: One hundred patients suffering from recurrent implantation failure in intracytoplasmic sperm injection (ICSI) were included in the study. The patients were randomly allocated into two groups. The intervention group consisted of 50 patients who received intrauterine injected with granulocyte colony-stimulating factor (G-CSF). The other group (the control group) consisted of 50 patients and injected with intrauterine Human Chorionic Gonadotropins (HCG). Both groups received the interventions at ovum pick-up day. The main outcome was the clinical pregnancy rate which has been evaluated after 2 weeks of the positive pregnancy test. The secondary outcome was an ultrasound image of the gestational sac after 6 weeks of pregnancy.

Eligibility criteria: Inclusion Criteria:

* Females suffering from recurrent implantation failure and undergoing ICSI

Exclusion Criteria:

* presence of comorbidity as diabetes, hypertension, heart diseases, or endocrine disorders

Primary outcomes:
measure: clinical pregnancy rate
timeFrame: after 14 days from positive pregnancy test
Secondary outcomes:
measure: ultrasound image of Gestational sac
timeFrame: 6 weeks of pregnancy
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00694954: Capsule Endoscopy vs Standard of Care for Obscure Intestinal Bleeding
Official title: A Randomized Controlled Trial of Capsule Endoscopy vs Standard Care in Patients With Iron Deficiency Anemia With Suspected Obscure / Occult Gastrointestinal Bleeding
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Iron Deficiency Anemia
Keywords: Iron deficiency anemia
Wireless capsule endoscopy
Obscure-occult gastrointestinal bleeding
Lead sponsor: University of Calgary
Sponsor class: OTHER
Collaborators: name: Alberta Heritage Foundation for Medical Research
name: Calgary Health Region
First posted: 2008-06-11
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The role of capsule endoscopy (CE) in patients with obscure / occult gastrointestinal (GI) bleeding remains unclear. This pragmatic randomized controlled trial is designed to determine the diagnostic yield and clinical outcomes of patients with obscure GI bleeding who receive CE compared to those who receive usual standard care.

Detailed description: Patients with iron deficiency anemia from suspected occult GI bleeding will be randomized to receive CE or usual standard care following a negative gastroscopy and colonoscopy. Our primary outcome measure (diagnostic yield) and secondary outcome measures (noted below) will be determined after one year of followup. Patients with have a minimum of one year of clinical followup. Direct health care costs in each arm of the study will be determined after a minimum of two years of followup.

An economic evaluation based on the results of the clinical trial is also planned.

Eligibility criteria: Inclusion Criteria:

1. Adult patients age over 18years with iron deficiency anemia (IDA). IDA is defined as hemoglobin \<137g/L in men or \<120g/L in women with serum ferritin level \<22ug/L in men and \<10ug/L in women.
2. Eligible patients should have a negative gastroscopy and negative colonoscopy within 1 year prior to entry into study.
3. Negative celiac screen and /or negative small bowel biopsies

Exclusion Criteria:

1. Overt gastrointestinal bleeding
2. Premenopausal women with menorrhagia
3. Known or suspected small bowel obstruction
4. Serious medical co-morbidities precluding surgery given the risk of capsule impaction
5. Pregnancy
6. Inability to provide informed consent

Primary outcomes:
measure: diagnostic yield
timeFrame: 48 weeks
Secondary outcomes:
measure: number of blood transfusions
timeFrame: 48 weeks
measure: number of hospitalizations for GI bleeding/anemia
timeFrame: 48 weeks
measure: number of GI-related procedures and investigations
timeFrame: 48
measure: procedure-related complications
timeFrame: 48
measure: quality of life
timeFrame: 48
measure: health care costs
timeFrame: 2 years
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: University of Calgary
state: Alberta
Study officials:
affiliation: University of Calgary
name: Catherine J. Dube, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03427554: To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris
Official title: A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing TRETINOIN CREAM, 0.1% to RETIN-A® (TRETINOIN) CREAM, 0.1% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Acne Vulgaris
Lead sponsor: Taro Pharmaceuticals USA
Sponsor class: INDUSTRY
First posted: 2018-02-09
Enrollment: 455
Sex: ALL
Minimum age (years): 12
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Bioequivalence study comparing Tretinoin Cream, 0.1% to RETIN-A®.

Detailed description: A Multi-center, Double-Blind, Randomized, Placebo controlled, Parallel-Group study, comparing TRETINOIN CREAM, 0.1% (TARO PHARMACEUTICALS U.S.A., INC.) to RETIN-A® (TRETINOIN) CREAM, 0.1% (VALEANT) and both active treatments to a Placebo Control in the treatment of Acne Vulgaris

Eligibility criteria: Inclusion Criteria:

* Healthy male or non pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris.
* Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the Investigator's Global Assessment (IGA).
* Subjects must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits.

Exclusion Criteria:

* Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.

Primary outcomes:
measure: Demonstration of Bioequivalence
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Charlotte
country: United States
facility: Catawba Research, LLC
state: North Carolina
Study officials:
affiliation: Catawba Research
name: Zaidoon A Al-Zubaidy
role: STUDY_DIRECTOR
References:
Clinical trial NCT01987154: Tolerance of an Extensively Hydrolyzed Protein Infant Formula Versus a Premature Infant Formula
Official title: Tolerance of an Extensively Hydrolyzed Protein Infant Formula Versus a Premature Infant Formula
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Feeding Intolerance
Lead sponsor: Mead Johnson Nutrition
Sponsor class: INDUSTRY
First posted: 2013-11-19
Enrollment: 61
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: To evaluate the use of a hypoallergenic infant formula containing an extensively hydrolyzed protein source for routine nutrition.


Eligibility criteria: Inclusion Criteria:

* Premature infant 28 to 33 weeks gestational age, inclusive, at birth
* Infant has never received enteral feedings or current enteral intake is less than 30 mL/kg/day
* Birth weight is greater than or equal to 700g to 1750g
* Appropriate birth weight for gestational age
* Singleton or twin birth
* Signed Informed consent

Exclusion Criteria:

* Infant's mother plans to exclusively breast feed
* 5 minute APGAR score is less than or equal to 4
* Major surgery that required general anesthesia prior to randomization
* Ventilator-dependent or requiring greater than 40% FiO2 on day of randomization
* Grade III or IV intraventricular hemorrhage diagnosed prior to randomization
* Infant is currently participating in another clinical study

Primary outcomes:
measure: Enteral intake (ml/kg/day)
timeFrame: Daily for 14 days
Secondary outcomes:
measure: Body Weight (g)
timeFrame: Daily for 14 days
measure: Feeding Tolerance
timeFrame: Daily for 14 days
measure: Respiratory status
timeFrame: Daily for 14 days
measure: Gut Inflammation
timeFrame: Once at Study Day 14
measure: Confirmed or suspected sepsis or necrotizing enterocolitis
timeFrame: Daily for 14 days
measure: Date of hospital discharge
timeFrame: Once at hospital discharge
measure: Growth
timeFrame: Study Days 1, 7, and 14
Other outcomes:
Locations:
city: Bari
country: Italy
facility: Azienda Ospedaliera "Ospedale Policlinico Consorziale" di Bari
state: Apulia
Study officials:
affiliation: Universita degli Studi di Bari
name: Mariella Baldassarre, M.D.
role: PRINCIPAL_INVESTIGATOR
References: